# Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in myasthenia gravis: Patient preference and satisfaction from a Phase 3b study

AAN 2025, San Diego, CA, USA; April 5–9, 2025

Miriam Freimer[1], Urvi Desai[2], Raghav Govindarajan[3], Min K. Kang[4], Shaida Khan[5], Bhupendra Khatri[6], Todd Levine[7], Samir Macwan[8], Perry B. Shieh[9], Michael D. Weiss[10], Jos Bloemers[11], Babak Boroojerdi[12], Eumorphia Maria Delicha[13], Andreea Lavrov[12], Puneet Singh[14] and James F. Howard Jr.[15] on behalf of the MG0017 study team

[1]Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; [2]Atrium Health, Wake Forest University, Charlotte, NC, USA; [3]HSHS St. Elizabeth's Hospital, O'Fallon, IL, USA; [4]Department of Neurology, University of California San Francisco, San Francisco, CA, USA; [5]Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA; [6]The Regional MS Center and Center for Neurological Disorders, Milwaukee, WI, USA; [7]HonorHealth Neurology, Bob Bové Neuroscience Institute, Scottsdale, AZ, USA; [8]Department of Neurology, Eisenhower Health, Rancho Mirage, CA, USA; [9]Department of Neurology and Pediatrics, University of California Los Angeles, Los Angeles, CA, USA; [10]Department of Neurology, University of Washington Medical Center, Seattle, WA, USA; [11]UCB, Brussels, Belgium; [12]UCB, Monheim, Germany; [13]UCB, Braine-l'Alleud, Belgium; [14]UCB, Slough, UK; [15]Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

## Introduction

- Antibody-based complement C5 inhibitors for the treatment of gMG are administered by IV infusion by HCPs
- There remains a need for alternative therapeutic options for patients with gMG, especially for those who find IV administration challenging, or who are in underserved or rural populations where economic and logistic access to IV infusions is prohibitive
- Zilucoplan, a 15-amino acid macrocyclic peptide complement C5 inhibitor, is self-administered by daily SC injection, which some patients may prefer to IV complement C5 inhibitors
  - Zilucoplan is approved for the treatment of patients with anti-AChR Ab+ gMG in the United States[1]
- Here, we report treatment satisfaction and patients' preference in adults with anti-AChR Ab+ gMG after switching to zilucoplan from IV complement C5 inhibitors

## Methods

- MG0017 (NCT05514873) was a Phase 3b, open-label, single arm study with a 12-week main treatment period and an optional extension period of daily SC zilucoplan 0.3 mg/kg in patients who were willing to switch from an antibody-based, IV, complement C5 inhibitor (eculizumab or ravulizumab) (**Figure 1**)
- The primary safety endpoint was incidence of TEAEs
- Secondary efficacy endpoints included change from baseline in MG-ADL total score to Week 12
- Other patient-reported outcomes included treatment satisfaction (measured using the TSQM-9; scored from 0 to 100) and patient preference for IV or SC complement C5 inhibitors, assessed at Week 12 (both exploratory endpoints)
- Complement inhibition at baseline and Week 12 was assessed using a sheep red blood cell lysis assay

## Results

- Patient demographics and baseline disease characteristics are presented in **Table 1**
- 26 patients enrolled in MG0017 and received zilucoplan
  - 16 patients switched from eculizumab and 10 switched from ravulizumab
  - Patients wanted to switch for a variety of reasons, including logistical challenges, lengthy infusion times and challenges with venous access (**Figure 2**)
- 23 patients completed the main treatment period and three had discontinued (two due to TEAEs [**Table 2**], the third due to non-compliance with study protocol)
- TEAEs were mostly mild in severity (**Table 2**)
- In the total population, there was a nominally significant improvement in MG-ADL score (**Figure 3**)
  - Clinically meaningful and nominally significant improvements were observed in MG-ADL scores in patients who switched from ravulizumab (**Figure 3**)
- At Week 12, MG symptoms were improved or unchanged in approximately 75% of patients (data not shown)[2]
- Over three-quarters of the study population preferred SC treatment
  - Of those who preferred SC treatment, about half were from the prior eculizumab subgroup and half from the prior ravulizumab subgroup (**Figure 4**)
- Mean TSQM-9 Global Satisfaction, Effectiveness and Convenience subscores all showed clinically meaningful increases from baseline at Week 12, except the Effectiveness subscore for prior eculizumab subgroup (**Figure 5**)
- In patients with both baseline and Week 12 TSQM-9 scores available, the mean percentage increases in score from baseline in the prior eculizumab, prior ravulizumab and the total population were
  - Global Satisfaction: 41.6% (n=13), 53.9% (n=10) and 47.0% (n=23)
  - Effectiveness: 15.3% (n=12), 49.6% (n=10) and 30.9% (n=22)
  - Convenience: 60.3% (n=13), 32.4% (n=10) and 48.2% (n=23)
- Complement inhibition increased from 93.5% at baseline to 98.5% at Week 12 with zilucoplan treatment in the total population
  - The increase in complement inhibition was particularly pronounced in the subgroup of patients who switched from ravulizumab (87.3% to 98.9%)

### Figure 1 Study design




*The last dose of IV complement C5 inhibitor administration could not occur beyond the screening visit (Day −14 ±3 days for patients receiving eculizumab or Day −56 ±3 days for patients receiving ravulizumab), to ensure approximately 2 weeks' or 8 weeks' interval, respectively, before the first SC zilucoplan administration. †Per investigator's judgment, with ≤2-point change in MG-ADL score at baseline compared with screening visit.

### Table 1 Demographics and baseline disease characteristics

| | | Zilucoplan 0.3 mg/kg (N=26) |
|---|---|---|
| Female, n (%) | | 13 (50.0) |
| Age at initial diagnosis, years, mean (min, max) | | 51.7 (7, 73) |
| Duration of disease from diagnosis, years, mean (min, max) | | 8.4 (0.8, 31.0) |
| MG-ADL score at baseline, mean (min, max) | | 4.5 (0, 13) |
| QMG score at baseline, mean (min, max) | | 10.1 (2, 23) |
| Baseline gMG therapy, n (%) | Cholinesterase inhibitors | 19 (73.1) |
| | Corticosteroids | 12 (46.2) |
| | Azathioprine, mycophenolate mofetil | 13 (50.0) |
| Prior IV complement C5 inhibitor treatment before switching to ZLP, n (%) | Eculizumab | 16 (61.5) |
| | Ravulizumab | 10 (38.5) |

### Table 2 Overview of TEAEs

| | Zilucoplan 0.3 mg/kg (N=26) |
|---|---|
| Any TEAE,* n (%) | 19 (73.1) |
| Amylase increase | 3 (11.5) |
| Diarrhea | 2 (7.7) |
| Injection-site pain | 2 (7.7) |
| Lipase increase | 2 (7.7) |
| Nausea | 2 (7.7) |
| Pain | 2 (7.7) |
| Sinusitis | 2 (7.7) |
| Serious TEAE, n (%) | 1 (3.8)† |
| Treatment-related TEAE, n (%) | 6 (23.1) |
| TEAE resulting in permanent withdrawal from zilucoplan, n (%) | 2 (7.7)† |
| Severe TEAE, n (%) | 3 (11.5) |

Safety set. Data are presented as n (%), where n=number of patients with TEAE. *Specific TEAEs listed are those occurring in ≥5% of patients. †Diverticulitis and pyelonephritis (both in the same patient), considered to be unrelated to zilucoplan by the investigator. ‡Injection-site pain, injection-site discoloration, pain, anxiety and fatigue (n=1) and reactivation of Epstein-Barr virus (n=1); the TEAEs of injection-site pain and discoloration that resulted in permanent withdrawal were deemed treatment-related by the investigator.

### Figure 2 Reasons patients wanted to switch from IV complement C5 inhibitors

| | Patients switching from eculizumab n=16 | Patients switching from ravulizumab n=10 | Total N=26 |
|---|---|---|---|
| Logistical challenges, including travel and time spent at a hospital | 7 (43.8) | 1 (10.0) | 8 (30.8) |
| Challenges with venous access | 2 (12.5) | 2 (20.0) | 4 (15.4) |
| Lengthy intravenous infusion | 3 (18.8) | 0 | 3 (11.5) |
| Other | 4 (25.0) | 7 (70.0) | 11 (42.3) |

**Eculizumab, other reasons for switching (n=4)**
**Wearing off**
**Loss of hair**
**Sick after infusions** and would like to try a different treatment
Happy with current treatment, but would like to **participate in a research study to help science**

**Ravulizumab, other reasons for switching (n=7)**
**Wearing off, less effective**
**Experiencing symptoms** about 1.5 weeks prior to next infusion
**Lack of efficacy**
Would like to **try a new treatment** to see if this would **improve MG symptoms**
Would like to **try an alternative** treatment
Recommended by doctor, **hates poking**
**Easier** administration

Data are presented as n (%). 'Other' was an option for investigators to write free text. Answers here are written verbatim.

### Figure 3 MG-ADL score improved to Week 12, particularly in patients switching from ravulizumab




*p-values are nominal. Analysis by prior IV complement C5 inhibitor was *post hoc*. †A 2-point change in MG-ADL score is considered clinically meaningful.[3]

### Figure 4 Zilucoplan SC injections were preferred by the majority of patients




*The verbatim question asked at the end of the study was *"Think about your experience of the subcutaneous treatment you received during the clinical trial compared with your previous intravenous treatment. All things considered, which treatment did you prefer? (please select one answer): Intravenous infusion/subcutaneous injection/no preference"*.

### Figure 5 Clinically meaningful improvements in TSQM-9 scores[4] for a) Global Satisfaction, b) Effectiveness and c) Convenience were observed at Week 12




The Global Satisfaction, Effectiveness and Convenience domains and scoring in TSQM-9 are the same as those used in TSQM v1.4, therefore use of the published meaningful change thresholds for TSQM v1.4 is considered appropriate here.[4] The published meaningful change thresholds for Global Satisfaction, Effectiveness and Convenience are 12.24, 9.99 and 10.81, respectively.[4] Numerical discrepancies in this figure are due to rounding of data.

## Summary and conclusions

Switching from IV complement C5 inhibitors (eculizumab or ravulizumab) to SC zilucoplan was well tolerated

Following a treatment switch from IV eculizumab or ravulizumab to zilucoplan, MG-ADL total score improved, and this was clinically meaningful for patients switching from ravulizumab

Overall treatment satisfaction increased after switching from IV complement C5 inhibitors to SC zilucoplan

- In the Effectiveness subdomain of TSQM-9, patients switching from ravulizumab showed the greatest improvement
- In the Convenience subdomain, patients switching from eculizumab showed the greatest improvement

More than three-quarters of patients preferred SC to IV treatment

For HCPs and their patients who are considering self-administered daily SC injections, switching to zilucoplan from IV complement C5 inhibitors is feasible

**Abbreviations:** Anti-AChR Ab+, anti-acetylcholine receptor autoantibody-positive; BL, baseline; C5, component 5; CFB, change from baseline; CI, confidence interval; gMG, generalized myasthenia gravis; HCP, healthcare professional; IV, intravenous; LS, least squares; MG, myasthenia gravis; MG-ADL, Myasthenia Gravis Activities of Daily Living; QMG, Quantitative Myasthenia Gravis; SC, subcutaneous; sRBC, sheep red blood cell; TEAE, treatment-emergent adverse event; TSQM-9, 9-item Treatment Satisfaction Questionnaire for Medication; ZLP, zilucoplan.

**Acknowledgments:** This study was funded by UCB. The authors acknowledge Qudsia Ehsan, BSc, and Julia Stevens, PhD, of Ogilvy Health, London, UK, for editorial assistance, which was funded by UCB. The authors thank Veronica Porkess, PhD, of UCB for publication and editorial support. The authors thank the patients and their caregivers, in addition to the investigators and their teams who contributed to this study.

**Author disclosures:** Miriam Freimer has served as a paid Consultant for Arcelix, argenx and UCB. She receives research support from Abcuro, Alnylam Pharmaceuticals, argenx, Avidity Biosciences, COUR Pharmaceuticals, Dianthus Therapeutics, Fulcrum Therapeutics, Johnson & Johnson Innovative Medicine, the NIH, ReneGen Biosciences and UCB. Raghav Govindarajan has served on advisory boards for argenx, Janssen Pharmaceuticals, Roche and UCB, and participated in speaker bureaus for Alexion Pharmaceuticals, argenx and UCB. Min K. Kang receives research support from UCSF and has served on advisory boards for Alexion Pharmaceuticals, Johnson & Johnson and UCB. She has received honoraria from AcademicCME. Shaida Khan has served as a paid Consultant for UCB and has served on advisory boards for argenx and UCB. She receives research support from the Fichtenbaum Charitable Trust. Bhupendra Khatri has received research and/or consulting financial compensation from Alexion Pharmaceuticals, argenx, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Novartis, Sanofi Genzyme (now Sanofi), Terumo BCT, TG Therapeutics and UCB. Todd Levine has nothing to disclose. Samir Macwan has received personal compensation for serving as a Consultant for Alexion Pharmaceuticals, argenx, KalaFusion and UCB. He has received personal compensation for serving on a speakers' bureau for AbbVie, Alexion Pharmaceuticals, argenx and Grifols. The institution of Dr. Macwan has received research support from Alexion Pharmaceuticals and Dysimmune Diseases Foundation. Perry B. Shieh has nothing to disclose. Michael D. Weiss has received honoraria for serving on scientific advisory boards for Alexion Pharmaceuticals, Amylyx Pharmaceuticals, argenx, Biogen, Immunovant, Mitsubishi Tanabe Pharma and Ra Pharmaceuticals (now UCB), consulting honoraria from CSL Behring and Cytokinetics, and speaker honoraria from Soleo Health. He also serves as a special government employee for the Food and Drug Administration. Jos Bloemers, Babak Boroojerdi and Andreea Lavrov are employees and shareholders of UCB. Eumorphia Maria Delicha is an employee of UCB. Puneet Singh is an employee and shareholder of UCB and a shareholder and previous employee of GSK. James F. Howard Jr. has received research support (paid to his institution) from Ad Scientiam, Alexion/AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, the Centers for Disease Control and Prevention, the Muscular Dystrophy Association, the Myasthenia Gravis Foundation of America, the National Institutes of Health, NMD Pharma, and UCB; has received honoraria/consulting fees from AcademicCME, Alexion/AstraZeneca Rare Disease, Amgen, argenx, Biohaven Ltd, Biologix Pharma, CheckRare CME, CorEvitas, Curie Bio, Hansa Biopharma, Medscape CME, Merck EMD Serono, Novartis, PeerView CME, Physicians' Education Resource (PER) CME, PlatformQ CME, Regeneron Pharmaceuticals, Sanofi US, TG Therapeutics, Toleranzia AB and UCB; and has received non-financial support from Alexion/AstraZeneca Rare Disease, argenx, Biohaven Ltd, Cartesian Therapeutics, Toleranzia AB and UCB.

**References:** 1. Zilbrysq US PI. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216834s001lbl.pdf Accessed March 2025. 2. Freimer M, et al. Switching to subcutaneous zilucoplan from IV complement component 5 inhibitors in myasthenia gravis: A Phase 3b study. MGFA 55 2024. Poster MG27. 3. Muppidi S, et al. Muscle Nerve 2011; 44:727–731. 4. Greene N, et al. J Patient Rep Outcomes. 2023;7(1):61.

Please use this QR code to download a PDF of the poster.